European Medicines Agency

The European Medicines Agency building
#Accelerated assessment #Committee for Medicinal Products for Human Use #European Medicines Agency #Rare disease

EMA accelerates assessment of drug for rare disease APDS

A potential new treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) has been validated for scientific evaluation under an accelerated assessment by the Committee for Medicinal Products for Human Use (CHMP).  Pharming’s investigational drug leniolisib, a selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, will be evaluated as a therapy in adolescents… Read More

#News #Regulatory